REGN Financial Facts
Net product sales: 857.47MCost of goods sold: 29.9M
See Full Income Statement
Total current liabilities: 961.19M
Common Stock: 107K
See Full Balance Sheet
Regeneron Pharmaceuticals, Inc. (REGN) Earnings
|
Expand Research on REGN
| Next EPS Date | 8/5/21 *Est. | EPS Growth Rate | +49.8% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +15.0% | Revenue Growth Rate | +38.3% *Last Qtr. |
| Average % Move 1-Wk after EPS | -2.5% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/6/21 |  |
Q121 | $9.89 | $9.00 | +$0.89 | $2.53B | $2.55B | N/A |  | | Details |
| 2/5/21 | |
Q420 | $9.53 | $8.43 | +$1.10 | $2.42B | $2.42B | N/A | | | Details |
| 11/5/20 | |
Q320 | $8.36 | $7.13 | +$1.23 | $2.29B | $2.09B | N/A | | | Details |
| 8/5/20 | |
Q220 | $7.16 | $5.98 | +$1.18 | $1.95B | $1.74B | N/A | | | Details |
| 5/5/20 | |
Q120 | $6.60 | $6.13 | +$0.47 | $1.83B | $1.76B | N/A | | | Details |
| 2/6/20 | |
Q419 | $7.50 | $6.92 | +$0.58 | $2.17B | $2.11B | N/A | | | Details |
| 11/5/19 | |
Q319 | $6.67 | $6.36 | +$0.31 | $2.05B | $1.99B | N/A | | | Details |
| 8/6/19 | |
Q219 | $6.02 | $5.41 | +$0.61 | $1.93B | $1.8B | N/A | | | Details |
